Summary:
Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of IONIS-AGT-LRX, an Antisense Inhibitor of Angiotensinogen Production Administered Subcutaneously for 12 Weeks to Hypertensive Patients with Uncontrolled Blood Pressure
Qualified Participants May Receive:
If you qualify, you will get compensated up to $2500 for your participation. The study includes 19 home visits, and 1 home visit for a total of 20 visits. You will get compensated $125 for each visit you complete.